BeiGene

BeiGene is a global biopharmaceutical company founded in 2010, focused on discovering, developing, manufacturing, and commercializing innovative cancer therapies. The company aims to improve treatment outcomes and patient access to cancer medicines worldwide. With over 3,400 employees, BeiGene operates research and development facilities and commercial offices across China, the United States, and Europe. The company's product portfolio includes BRUKINSA, a selective Bruton's tyrosine kinase inhibitor for various B-cell malignancies, and TEVIMBRA, an anti-PD-1 monoclonal antibody for solid tumors. BeiGene also has a robust pipeline with 32 clinical or commercial stage assets, including late-stage candidates targeting a range of cancers. The company conducts clinical trials in over 35 countries, reflecting its commitment to international standards in drug development and its strong market presence in major pharmaceutical markets.